دورية أكاديمية
Longitudinal assessment of urinary ALCAM, HPX, and PRDX6 in Korean patients with systemic lupus erythematosus: implications for disease activity monitoring and treatment response.
| العنوان: | Longitudinal assessment of urinary ALCAM, HPX, and PRDX6 in Korean patients with systemic lupus erythematosus: implications for disease activity monitoring and treatment response. |
|---|---|
| المؤلفون: | Kim JW; Department of Rheumatology, Ajou University School of Medicine, Suwon, Republic of Korea., Baek WY; Department of Rheumatology, Ajou University School of Medicine, Suwon, Republic of Korea., Jung JY; Department of Rheumatology, Ajou University School of Medicine, Suwon, Republic of Korea., Kim HA; Department of Rheumatology, Ajou University School of Medicine, Suwon, Republic of Korea., Lee SW; Department of Rheumatology, Ajou University School of Medicine, Suwon, Republic of Korea., Suh CH; Department of Rheumatology, Ajou University School of Medicine, Suwon, Republic of Korea.; Department of Molecular Science and Technology, Ajou University, Suwon, Republic of Korea. |
| المصدر: | Frontiers in immunology [Front Immunol] 2024 Jun 10; Vol. 15, pp. 1369385. Date of Electronic Publication: 2024 Jun 10 (Print Publication: 2024). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Biomarkers*/urine , Lupus Erythematosus, Systemic*/urine , Lupus Erythematosus, Systemic*/diagnosis , Peroxiredoxin VI*/urine, Humans ; Female ; Male ; Adult ; Republic of Korea ; Middle Aged ; Fetal Proteins/urine ; Longitudinal Studies ; Severity of Illness Index ; Young Adult ; Antigens, CD/urine ; ROC Curve ; Cell Adhesion Molecules, Neuronal/urine ; Case-Control Studies ; Lupus Nephritis/urine ; Lupus Nephritis/diagnosis ; Activated-Leukocyte Cell Adhesion Molecule |
| مستخلص: | Introduction: This study aimed to demonstrate the potential of activated leukocyte cell adhesion molecule (ALCAM), hemopexin (HPX), and peroxiredoxin 6 (PRDX6) as urine biomarkers for systemic lupus erythematosus (SLE). Methods: Urine samples were collected from 138 Korean patients with SLE from the Ajou Lupus Cohort and 39 healthy controls (HC). The concentrations of urine biomarkers were analyzed using enzyme-linked immunosorbent assay kits specific for ALCAM, HPX, and PRDX6, respectively. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic utility, and Pearson's correlation analysis was conducted to assess the relationships between the disease activity and urine biomarkers. Results: Patients with SLE and patients with lupus nephritis (LN) showed significantly elevated ALCAM, HPX, and PRDX6 levels compared with HCs. ALCAM, HPX, and PRDX6 showed significant diagnostic values, especially for lupus nephritis (LN), with areas under the receiver operating characteristic curve for LN was 0.850 for ALCAM (95% CI, 0.778-0.921), 0.781 for HPX (95% CI, 0.695-0.867), and 0.714 for PRDX6 (95% CI, 0.617-0.812). Correlation analysis revealed that all proteins were significantly associated with anti-double stranded DNA antibody (ALCAM, r = 0.350, p < 0.001; HPX, r = 0.346, p < 0.001; PRDX6, r = 0.191, p = 0.026) and SLEDAI (ALCAM, r = 0.526, p < 0.001; HPX, r = 0.479, p < 0.001; PRDX6, r = 0.262, p = 0.002). Results from the follow-up of the three biomarker levels in these patients revealed a significant decrease, showing a positive correlation with changes in SLEDAI-2k scores (ALCAM, r = 0.502, p < 0.001; HPX, r = 0.475, p < 0.001; PRDX6, r = 0.245, p = 0.026), indicating their potential as indicators for tracking disease activity. Discussions: Urinary ALCAM, HPX, and PRDX6 levels have diagnostic value and reflect disease activity in Korean patients with SLE, emphasizing their potential for non-invasive monitoring and treatment response evaluation. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. (Copyright © 2024 Kim, Baek, Jung, Kim, Lee and Suh.) |
| References: | Front Immunol. 2022 May 26;13:885307. (PMID: 35720325) Nat Commun. 2020 May 4;11(1):2197. (PMID: 32366845) Arthritis Rheum. 2012 Aug;64(8):2677-86. (PMID: 22553077) J Immunol. 2004 Aug 15;173(4):2262-70. (PMID: 15294938) Pediatr Rheumatol Online J. 2017 Oct 13;15(1):74. (PMID: 29029629) Antioxidants (Basel). 2018 Nov 24;7(12):. (PMID: 30477202) J Crohns Colitis. 2017 Jul 01;11(7):871-884. (PMID: 28199527) Ann Rheum Dis. 2022 Jun;81(6):845-853. (PMID: 35236659) Arthritis Res Ther. 2020 May 27;22(1):122. (PMID: 32460901) Front Immunol. 2016 Jan 06;6:635. (PMID: 26779182) Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):E524-E533. (PMID: 28069965) Front Immunol. 2022 Oct 12;13:987385. (PMID: 36311744) Lancet. 2014 Nov 22;384(9957):1878-1888. (PMID: 24881804) N Engl J Med. 2011 Dec 1;365(22):2110-21. (PMID: 22129255) Front Immunol. 2022 Sep 09;13:967944. (PMID: 36159854) Front Pediatr. 2022 Jul 29;10:974049. (PMID: 35967565) J Clin Med. 2021 Jul 17;10(14):. (PMID: 34300326) J Crit Care. 2015 Jun;30(3):525-30. (PMID: 25588861) Lupus. 2019 Mar;28(3):265-272. (PMID: 30712490) Lupus Sci Med. 2022 May;9(1):. (PMID: 35568436) Pediatr Nephrol. 2023 Aug;38(8):2679-2688. (PMID: 36715772) DNA Cell Biol. 2002 Apr;21(4):297-306. (PMID: 12042069) Arthritis Rheumatol. 2015 Nov;67(11):3058-69. (PMID: 26211509) Front Immunol. 2022 Aug 24;13:910993. (PMID: 36091001) J Immunol. 2013 Jul 1;191(1):369-77. (PMID: 23729438) Arthritis Rheumatol. 2019 Sep;71(9):1400-1412. (PMID: 31385462) Arch Biochem Biophys. 2017 Mar 1;617:68-83. (PMID: 27932289) Arthritis Res Ther. 2023 Sep 8;25(1):165. (PMID: 37684700) Autoimmune Dis. 2012;2012:834291. (PMID: 22888407) Biom J. 2005 Aug;47(4):458-72. (PMID: 16161804) Ann Transl Med. 2018 Nov;6(Suppl 1):S41. (PMID: 30613616) Rheumatology (Oxford). 2020 Sep 1;59(9):2237-2249. (PMID: 31722419) Kidney Int. 2022 Oct;102(4):845-865. (PMID: 35788359) Arthritis Care Res (Hoboken). 2016 Jul;68(7):1003-11. (PMID: 26473509) |
| فهرسة مساهمة: | Keywords: ALCAM; HPX; PRDX6; systemic lupus erythematosus; urine biomarker |
| المشرفين على المادة: | 0 (Biomarkers) 0 (ALCAM protein, human) EC 1.11.1.15 (Peroxiredoxin VI) 0 (Fetal Proteins) EC 1.11.1.15 (PRDX6 protein, human) 0 (Antigens, CD) 0 (Cell Adhesion Molecules, Neuronal) 0 (Activated-Leukocyte Cell Adhesion Molecule) |
| تواريخ الأحداث: | Date Created: 20240625 Date Completed: 20240625 Latest Revision: 20240715 |
| رمز التحديث: | 20240715 |
| مُعرف محوري في PubMed: | PMC11194348 |
| DOI: | 10.3389/fimmu.2024.1369385 |
| PMID: | 38915417 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2024.1369385 |